ALKBH5 and acute myeloid leukemia: Collectively, these studies clearly suggest that the m6A-eraser protein ALKBH5 promotes leukemogenesis, and therefore targeting ALKBH5 using selective inhibitors (Selberg et al., 2021, PMID 34056479) could be a potential approach to control AML in humans (Figure 4, Table 2 and Table 3) [52].